KAO JOHN E sold $2.2M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 172,600 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at $12.96 ($2.24M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Sep 12, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Bearish
high confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCBearishMed
01

Why it matters

The transaction reduces insider ownership by roughly 22%, which may be interpreted as a negative signal by investors and could trigger short‑term price weakness.

02

Market read

Insider sell of this magnitude by the CEO is a material event for ALHC, likely influencing short‑term trading sentiment.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed may be driving the sell.

Relevance 5/10Novelty 8/10Timing: after market on 2026-09-10

Background

Form 4 filings provide the first public disclosure of insider transactions; this sale is the first report of the CEO's recent share reduction.

Company-level read

Ticker impact

$ALHCBearishHigh confidence
Context

CEO John E. Kao sold 172,600 shares for $2.24M via a 10b5‑1 plan, reducing his stake to 618,166 shares.

Expected impact

Potential short‑term downside pressure; traders may consider short positions or reduce long exposure.

Evidence & confidence

The sale size exceeds $2M and is executed under a pre‑arranged plan, indicating a material insider transaction that markets typically view as bearish.

Market effects

May weigh on other healthcare small‑caps as insider sells can raise sector‑wide risk concerns.

Limited to U.S. markets; no broader regional effect.

Low; impact confined to Alignment Healthcare and its immediate peers.

Counterpoint

The sale could be purely liquidity‑driven under the 10b5‑1 plan, not a confidence signal.

Key entities

  • Alignment Healthcare, Inc.

    U.S. listed healthcare company (ticker ALHC).

  • John E. Kao

    Chief Executive Officer of Alignment Healthcare.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.